Oxandrolone 10mg/tab 100 Tabletten by Sterling Knight Pharmaceuticals

Usage

1. Step 1: Complete a full pre-PCT bloodwork panel — LH, FSH, total testosterone, ALT, AST, and lipid profile — before the first Sterling Knight Oxandrolone tablet to establish individual baseline values.
2. Step 2: Initiate Oxandrolone at 20 mg per day (two tablets) on the same day as your SERM-based PCT commences, not before, to avoid running the oral androgen without the gonadotropin recovery component in place.
3. Step 3: Split daily intake into two 10 mg administrations timed with morning and afternoon meals to distribute androgen-receptor exposure across the highest-output waking hours and reduce hepatic peak load.
4. Step 4: At the Week 4 mark, obtain a follow-up LH, FSH, and total testosterone panel. Use this data — not a calendar date — to determine whether to maintain the current dose or initiate the one-tablet taper step.
5. Step 5: Reduce to 10 mg per day (one tablet) once LH and FSH values trend upward toward the mid-reference range; hold at this reduced dose for one further week before full cessation.
6. Step 6: Complete a final post-PCT bloodwork check two weeks after the last Oxandrolone tablet to confirm HPG-axis recovery metrics are within normal physiological range and document the outcome for future cycle planning reference.

Warnings

Frequently asked questions

How does Oxandrolone fit into a modern PCT protocol compared to running testosterone?

Oxandrolone provides androgen-receptor-mediated nitrogen retention and anti-catabolic support during PCT without the HPG-axis suppression that accompanies even low-dose exogenous testosterone. Modern PCT frameworks favour Oxandrolone in this bridging role precisely because SERM-driven gonadotropin recovery proceeds with less direct competition from a lower-suppression oral androgen compared to ester-based testosterone approaches.

What SERMs are typically combined with Oxandrolone in evidence-informed PCT plans?

Clomiphene citrate (Clomid) and tamoxifen citrate (Nolvadex) remain the SERM backbone of most evidence-informed male PCT plans. Both agents work at pituitary and hypothalamic oestrogen receptors to restore LH and FSH output. Because Oxandrolone's mechanism operates through androgen receptors rather than oestrogen receptors, it layers into the same PCT framework without pharmacological overlap with either SERM compound.

How long should an Oxandrolone PCT bridge phase run and when should it be tapered?

A structured PCT bridge phase with Oxandrolone typically runs four to six weeks at 10–20 mg per day. The taper trigger should be a bloodwork checkpoint at week four covering LH, FSH, and total testosterone — not a fixed calendar date. When LH and FSH values trend upward and total testosterone approaches the lower reference range, a one-tablet weekly step-down over the final two weeks is the standard reduction approach.

Why does the 10mg tablet strength matter specifically during a PCT taper?

During a PCT taper, the ability to reduce daily androgen exposure in precise 10 mg increments without cutting tablets is operationally significant. Higher-strength tablet formats cannot be accurately halved or quartered to achieve the granular weekly reductions that a bloodwork-guided taper demands. The Sterling Knight Pharmaceuticals 10 mg unit is the lowest uniform tablet strength in this Oxandrolone product group, making it uniquely suited to dose-stepping within a recovery context.

Does the 100-tablet jar provide enough supply for a complete PCT Oxandrolone phase?

Yes. At 20 mg per day for six weeks, a 100-tablet pack at 10 mg per tablet delivers exactly 1,200 mg of Oxandrolone — covering the full phase plus a two-week one-tablet-per-day step-down taper without requiring a second purchase. At a more conservative 10 mg per day, the same pack extends to a ten-week bridging window, accommodating extended recovery timelines for advanced athletes running longer blast phases beforehand. (2) angle_used

Manufacturer

Sterling Knight Pharmaceuticals has cultivated a feedback loop between its oral tablet product line and the structured sports community users who have incorporated those products into documented, bloodwork-monitored training protocols — a relationship that distinguishes the brand from manufacturers whose quality data remains inaccessible to end users. User-reported outcomes from PCT-context Oxandrolone use, catalogued across bodybuilding monitoring communities, consistently cite tablet-to-tablet consistency as the attribute most critical to bloodwork-guided taper protocols, where a single outlier tablet at variance with the declared 10 mg dose introduces variables that corrupt week-on-week recovery data. Sterling Knight Pharmaceuticals addresses this directly through per-batch HPLC potency confirmation applied before any lot leaves the production facility — a mandatory release gate rather than a periodic audit, meaning the sports community users who rely on the data can access lot-specific verification rather than a generalised brand-level quality claim. GMP-certified manufacturing conditions govern the compression and packaging process, with the brand's publicly accessible batch records reflecting the traceability standard that monitoring-focused PCT users have identified as the differentiating quality marker when selecting oral anabolics for recovery phase use.